Educational resources

Screen Shot 2019-10-22 at 11.25.04

Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

2020-02-17T09:20:00+00:00Commissioned by Takeda UK Ltd

This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.

20181214 Ozempic prescribing summary card cover half

Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA


Commissioned by Novo Nordisk Limited